ARTL

Artelo BiosciencesF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

No material screener or newswire events are stored for this ticker yet.

Sentiment decomposition

+56.8

30-day score

Company-55%

Macro-30%

Pulse-15%

The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.

Recent headlines

Headline

Time

Relevance

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

2026-05-14

23%

External coverage

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

2026-02-24

23%

External coverage

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

2025-12-23

23%

External coverage

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

2025-11-12

23%

External coverage

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

2025-10-27

External coverage

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

2025-09-03

23%

External coverage

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

2025-09-03

23%

External coverage

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

2025-08-25

23%

External coverage

As of 2026-05-14 • Updated scheduledSource: News desk